Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
SpringWorks Therapeutics
SpringWorks Therapeutics
(SWTX)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Ogsiveo
Nirogacestat
2023-11-27
2025-2043
Desmoid tumors
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
MIRDAMETINIB
liver diseases
,
hepatic insufficiency
,
healthy volunteers/patients
,
neurofibromatosis 1
,
neurofibromatoses
,
neurofibroma
,
neoplasms
,
plexiform neurofibroma
,
glioma
,
liposarcoma
,
myxoid liposarcoma
,
autonomic nervous system diseases
,
histiocytic sarcoma
Nirogacestat
neoplasms
,
ovarian neoplasms
,
granulosa cell tumor
,
desmoid tumors
,
fibroma
,
aggression
Bevifimod
neoplasms
,
recurrence
,
glioblastoma
,
glioma
,
lung neoplasms
,
neuroendocrine tumors
,
perivascular epithelioid cell neoplasms
LIFIRAFENIB
neoplasms
Nepidermin
actinic keratosis
,
keratosis
,
carcinoma
,
basal cell carcinoma
,
basal cell neoplasms
Endocrine
carcinoma
,
adrenocortical carcinoma
,
syndrome
,
pituitary acth hypersecretion
,
cushing syndrome
,
adrenocortical hyperfunction
Pd0332991
breast neoplasms
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use